摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-<6-(aminomethyl)pyridin-2-yl>-2-guanidinothiazole | 135450-75-8

中文名称
——
中文别名
——
英文名称
4-<6-(aminomethyl)pyridin-2-yl>-2-guanidinothiazole
英文别名
4-(6-Aminomethylpyridin-2-yl)-2-(diaminomethyleneamino)thiazole;2-[4-[6-(aminomethyl)pyridin-2-yl]-1,3-thiazol-2-yl]guanidine
4-<6-(aminomethyl)pyridin-2-yl>-2-guanidinothiazole化学式
CAS
135450-75-8
化学式
C10H12N6S
mdl
——
分子量
248.311
InChiKey
NATIZSVGHXNYHL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.7
  • 重原子数:
    17
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    144
  • 氢给体数:
    3
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-<6-(aminomethyl)pyridin-2-yl>-2-guanidinothiazole甲醇乙醇N,N-二甲基甲酰胺 为溶剂, 反应 6.0h, 生成 4-<6-<(2-cyano-3-methylguanidino)methyl>pyridin-2-yl>-2-guanidinothiazole
    参考文献:
    名称:
    Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury
    摘要:
    A series of 2-guanidino-4-pyridylthiazole derivatives were synthesized and evaluated for anti-aspirin-ulcer, gastric antisecretory, and histamine-H-2-receptor-antagonist activities. Several compounds showed superior anti-aspirin-ulcer activity to that of clinically used H-2-antagonists in the rat. Among them, 4-[6-(acetamidomethyl)pyridin-2-yl]-2-guanidinothiazole (8) demonstrated potent inhibitory activities against gastric lesions caused by two kinds of nonsteroidal antiinflammatory drugs, aspirin and indomethacin, respectively, in addition to strong antisecretory activity. Compound 8 possessed a preventable ability for the aspirin-induced reduction of the gastric mucosal blood flow at an intragastric administration of 32 mg/kg in the rat. On the other hand, famotidine (32 mg/kg) exhibited no significant effect and ranitidine (100 mg/kg) aggravated the blood flow in this system.
    DOI:
    10.1021/jm00027a007
  • 作为产物:
    参考文献:
    名称:
    Katsura Yousuke, Inoue Yoshikazu, Tomishi Tetsuo, Ishikawa Hirohumi, Taka+, J. Med. Chem, 37 (1994) N 1, S 57-66
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Thiazole derivatives, processes for the preparation thereof and
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US05371097A1
    公开(公告)日:1994-12-06
    A compound of the formula: ##STR1## wherein R.sup.1 is amino, acylamino, cyclo(lower)alkenylamino having amino and oxo, imido, triazolylamino, benzoisothiazolylamino, wherein each of said heterocyclicamino groups may be substituted by one or more substituent(s) selected from the group consisting of lower alkyl, amino and oxo, 2-cyano-3-lower alkylguanidino, 2-acyl-3-lower alkylguanidino, 2-acylguanidino, (1-lower alkylamino-2-nitrovinyl)amino, hydroxy, halogen, cyano, acyl, benzimidazolylthio, triazolyl substituted with amino, or a group of the formula: ##STR2## in which R.sup.4 is hydrogen, cyano, or acyl, and R.sup.5 is amino or lower alkoxy, R.sup.2 and R.sup.3 are each hydrogen, acyl or lower alkyl which may have halogen; or R.sup.2 and R.sup.3 are linked together to form lower alkylene, Y is ##STR3## in which R.sup.6 is hydrogen or halogen, and A is lower alkylene, or pharmaceutically acceptable salt thereof.
    该化合物的化学式为:##STR1## 其中R.sup.1为氨基,酰胺基,环(较低)烯基氨基,具有氨基和氧代的亚胺基,三唑基氨基,苯并异噻唑基氨基,其中所述的每个杂环氨基基团可以被选自较低烷基,氨基和氧代的一个或多个取代基取代,2-氰基-3-较低烷基胍基,2-酰基-3-较低烷基胍基,2-酰基胍基,(1-较低烷基氨基-2-硝基乙烯基)氨基,羟基,卤素,氰基,酰基,苯并咪唑基硫醚,三唑基被氨基取代,或一个化学式为:##STR2## 其中R.sup.4为氢,氰基或酰基,R.sup.5为氨基或较低烷氧基,R.sup.2和R.sup.3为氢,酰基或较低烷基,可以具有卤素;或R.sup.2和R.sup.3连接在一起形成较低烷基,Y为##STR3## 其中R.sup.6为氢或卤素,A为较低烷基,或其药学上可接受的盐。
  • New thiazole derivatives, and pharmaceutical composition comprising the
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US05364871A1
    公开(公告)日:1994-11-15
    A compound of the formula: ##STR1## wherein R.sup.1 is amino, ureido, lower alkanoylamino, lower alkoxycarbonylamino, lower alkylsulfonylamino, lower alkoxy(lower)alkanoylamino, mono or di or trihalo(lower)alkanoylamino, hydroxy(lower)alkanoylamino, protected hydroxy(lower)alkanoylamino, or a group of the formula: ##STR2## in which R.sup.4 is hydrogen or sulfamoyl, R.sup.5 is amino or lower alkoxy, R.sup.2 is hydrogen, lower alkyl, lower alkoxy(lower)alkyl, di(lower)alkylamino(lower)alkyl, (C.sub.3 -C.sub.7)-cycloalkyl, lower alkenyl or mono or di or trihalo(lower)alkyl; R.sup.3 is hydrogen or lower alkyl; or R.sup.2 and R.sup.3 are linked together to form lower alkylene, Y is ##STR3## in which R.sup.6 is hydrogen, A is lower alkylene, and W is NH; or R.sup.2 -W is piperidino or morpholino, or pharmaceutically acceptable salt thereof.
    该化合物的公式为:##STR1##其中R.sup.1为氨基,尿素基,较低的酰胺基,较低的烷氧羰基胺基,较低的烷基磺酰胺基,较低的烷氧(较低)酰胺基,单烷基或二或三卤代(较低)烷酰胺基,羟基(较低)烷酰胺基,保护羟基(较低)烷酰胺基,或公式:##STR2##其中R.sup.4为氢或磺酰基,R.sup.5为氨基或较低的烷氧基,R.sup.2为氢,较低的烷基,较低的烷氧(较低)烷基,二(较低)烷基氨基(较低)烷基,(C.sub.3-C.sub.7)-环烷基,较低的烯基或单烷基或二或三卤代(较低)烷基;R.sup.3为氢或较低的烷基;或者R.sup.2和R.sup.3相连形成较低的烷基,Y为##STR3##其中R.sup.6为氢,A为较低的烷基,W为NH;或R.sup.2-W为哌啶基或吗啉基,或其药学上可接受的盐。
  • New thiazole derivatives, processes for the preparation thereof and pharmaceutical compositon comprising the same
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0417751A2
    公开(公告)日:1991-03-20
    A compound of the formula : wherein R' is amino which may have suitable substituent ( s). hydroxy. halogen, cyano, acyl, heterocyclic thio, heterocyclic group or a group of the formula : in which R4 is hydrogen, cyano or acyl. and R5 is amino or lower alkoxy. R2 and R3 are each hydrogen, acyl or lower alkyl which may have halogen: or R2 and R3 are linked together to form lower alkylene. in which R6 is hydrogen or halogen, and A is bond or lower alkylene, provided that when R1 is amino which may have suitable substituent(s) and A is bond; or R1 is lower alkylthioureido and A is lower alkylene, then and pharmaceutically acceptable salt thereof, processes for their preparation and pharmaceutical compositions comprising them as an active. ingredient.
    式中的化合物 其中 R'为氨基,可具有合适的取代基(s)、羟基、卤素、氰基、酰基、杂环硫基、杂环基团或式......的基团: 其中 R4 是氢、氰基或酰基。 R5 是氨基或低级烷氧基。 R2 和 R3 各为氢、酰基或低级烷基,其中可含卤素:或 R2 和 R3 连接在一起形成低级亚烷基。 其中 R6 是氢或卤素,以及 A 是键或低级亚烷基、 条件是 当 R1 是氨基,可有适当的取代基,且 A 为键;或 R1 为低级烷基硫脲基,且 A 为低级亚烷基时 且 A 为低级亚烷基,则 以及它们的药学上可接受的盐、它们的制备方法和含有它们作为活性成分的药物组合物。
  • Katsura Yousuke, Inoue Yoshikazu, Tomishi Tetsuo, Ishikawa Hirohumi, Taka+, J. Med. Chem, 37 (1994) N 1, S 57-66
    作者:Katsura Yousuke, Inoue Yoshikazu, Tomishi Tetsuo, Ishikawa Hirohumi, Taka+
    DOI:——
    日期:——
  • THIAZOLE DERIVATIVES
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0575614A1
    公开(公告)日:1993-12-29
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-